CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Sophiris Bio Inc is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Sophiris Bio Inc
1258 Prospect St
Phone: (858) 777-1760p:858 777-1760 LA JOLLA, CA  92037-3609  United States Fax: (858) 412-5693f:858 412-5693

This company is no longer actively traded on any major stock exchange.

Business Summary
Sophiris Bio Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing products for the treatment of urological diseases. The Company is developing topsalysin (PRX302) as a treatment for the lower urinary tract symptoms of benign prostatic hyperplasia (BPH) commonly referred to as an enlarged prostate and as a treatment for localized low to intermediate risk prostate cancer. Topsalysin, a genetically modified recombinant protein, is delivered through ultrasound-guided injection directly into the prostate. This membrane-disrupting protein is selectively activated by enzymatically active prostate specific antigen (PSA), which is only present in the prostate, leading to localized cell death and tissue disruption without damage to neighboring tissue and nerves. This method of administration limits the circulation of the drug in the body. The Company has completed Phase III clinical trials of topsalysin.
(Source: 10-K)

Scores and Ratings
FRISK®
Score
Z''
Score
PAYCE®
Score
DBT
Index
Moody's
Rating
Fitch
Rating
DBRS
Rating
-Yes-----

Financials, News and Filings
Latest
Statement
Last
Audit

News
SEC
Filings
Bankruptcy
Filings
Suit &
Judgment
Filings
Tax
Lien
Filings
9/30/201912/31/2018YesYes---

Officers and Directors

Title

Name

Age
Title
Date
Start
Date
Non-Executive Independent Chairman of the Board Lars G.Ekman 71 1/1/2014 11/19/2010
President, Chief Executive Officer, Director Randall E.Woods 68 10/1/2012 8/16/2012
Chief Financial Officer Peter T.Slover 46 10/1/2012 10/1/2012
3 additional Officers and Directors records available in full report.

Business Names
Business Name
PRX
Sophiris Bio Corp.
SPHS

General Information
Number of Employees: 6 (As of 12/31/2018)
Outstanding Shares: 34,472,140 (As of 11/1/2019)
Shareholders: 10
Stock Exchange: OTC
Federal Tax Id: 981008712
Fax Number: (858) 412-5693


Copyright © 2023 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Friday, July 21, 2023